Associação entre Sarcopenia e Diabetes Mellitus: uma revisão sistemática.

Abstract

The natural aging process is a complex mechanism and implicates plenty of changes for the individual, which occur in the physical, psychic and social matters. It’s known that there is a relation between diseases and the aging effect in the organs, generating many signs, symptoms and alterations in body composition. The sarcopenia is one of the main body alterations that happens in angind and can be defined, according with the European Working Group on Sarcopenia in Older People, as low quantity of muscle mass, that could be accompanied of low muscle strength or loss of muscle function. With diabetes mellitus type 2 and sarcopenia being conditions that influences the whole landscape of health of individuals of the same age range and with mutual risk factors in common the study of the intersection of these two pathologies it’s needed with high accuracy. Goals: Elaborate a systematic review that could identify relevant associations between sarcopenia and diabetes mellitus type 2 that could improve clinical practice. Methods: Was made a bibliographic survey of articles on sarcopenia and diabetes mellitus type 2 in the electronic databases PUBMED, SCOPUS and Web Of Science, published between january of 2013 and august of 2017, including articles published in english, portuguese and spanish, made with human beings and with full text available. It was also made a secondary survey of informations and analyses of the quality of found studies. Results: The total prevalence of sarcopenia em diabetic patients of the selected studies was 32,11%, using various methods to diagnose sarcopenia. It was found alterations of muscular padrons in diabetic patients not found in non-diabetic patients, bigger alterations were found in individuals with higher HbA1C. It was seen association between metabolic syndrome and sarcopenia, more prominent em elderly people and more related to abdominal obesity. It was found positive clinical response with the utilization of incretin agonists, DPP-4 inhibitor and angiotensin receptor blocker. Conclusion: Sarcopenia still needs a better diagnostic padronization that respects ethnic differences among populations, highlighting muscle quality alterations on diabetic patients, it’s certain that the metabolic and glycemic control are important to slow sarcopenia progression and more studies are necessary to propose new treatment to those patients.